MaxCyte,
Inc.
("MaxCyte" or the "Company")
Grant of Options and
Restricted Stock Units
ROCKVILLE, MD, October 18, 2024: MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading,
cell-engineering focused company providing enabling platform
technologies to advance the discovery, development, and
commercialization of next-generation cell therapeutics and to
support innovative, cell-based research, announces that on 14
October 2024, Cynthia Collins, a non-executive director, has been
granted total of 97,698 options ("Option Grant") in respect of
common stock in the Company ("Common Stock"), and 51,679 restricted
stock units ("RSU"s), which were agreed in September pursuant to
Cynthia's appointment.
The Option Grant vests over three (3) years, with the
initial vesting of 1/3rd of the total after twelve (12)
months, and the remainder vesting monthly over the following 24
months. The Option Grant have an exercise period of 10 years
from date of grant, at which time they will expire, and have an
exercise price equal to the closing price of MaxCyte's stock on 14
October 2024, of $3.87 on the United States Nasdaq Stock
Exchange.
The RSUs vest at the end of twelve (12) months after
date of grant. (1 year cliff until fully vested).
About MaxCyte
At MaxCyte, we pursue cell
engineering excellence to maximize the potential of cells to
improve patients' lives. We have spent more than 20 years honing
our expertise by building best-in-class platforms, perfecting the
art of the transfection workflow, and venturing beyond today's
processes to innovate tomorrow's solutions. Our
ExPERT™ platform, which is based on our Flow
Electroporation®
technology, has been designed to support the
rapidly expanding cell therapy market and can be utilized across
the continuum of the high-growth cell therapy sector, from
discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™,
GTx™ and VLx ™; a portfolio of proprietary related
processing assemblies or disposables; and software protocols, all
supported by a robust worldwide intellectual property portfolio.
By providing our partners with the right technology, as well
as technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more
at maxcyte.com and
follow us on Twitter and LinkedIn.
MaxCyte Contacts:
|
US IR
Adviser
Gilmartin
Group
David
Deuchler, CFA
|
+1 415-937-5400
ir@maxcyte.com
|
|
Nominated Adviser and Joint
Corporate Broker
Panmure
Liberum
Emma Earl /
Freddy Crossley
Corporate
Broking
Rupert
Dearden
|
+44 (0)20 7886 2500
|
|
UK IR
Adviser
ICR
Consilium
Mary-Jane
Elliott
Chris
Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY
ASSOCIATED WITH THEM
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Cynthia Collins
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Common Stock of $0.01 each
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of options of common stock
|
|
c)
|
Price(s) and volume(s)
|
97,698 Options at an exercise price
of $3.87
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
N/A
|
|
|
|
|
- Price
|
N/A
|
|
|
|
|
e)
|
Date of the transaction
|
14 October 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Cynthia Collins
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
MaxCyte, Inc.
|
|
b)
|
LEI
|
54930053YHXULRFCU991
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
|
Grant of restricted stock units
|
|
|
|
|
Identification code
|
US57777K1060
|
|
|
|
|
b)
|
Nature of the transaction
|
Grant of options of restricted stock units
|
|
c)
|
Price(s) and volume(s)
|
51,679 restricted stock units, price
N/A
|
|
|
d)
|
Aggregated information
|
|
|
|
|
|
- Aggregated volume
|
N/A
|
|
|
|
|
- Price
|
N/A
|
|
|
|
|
e)
|
Date of the transaction
|
14 October 2024
|
|
f)
|
Place of the transaction
|
US Stock Exchange, Nasdaq
|
